6467.TWTAHO Pharma
泰合 · Biotech and medical · Taiwan Stock Exchange · Taiwan
The answers
Four readings from the exchange's own figures. Each line says what it is based on.
- Is it growing?n/a
- No monthly revenue report on file yet.
- Is it a good business?To watch
- It earns −56% a year on its shareholders' equity (H1 2026, annualised).
- Is it safe?Good
- Equity is 95% of its assets; the rest is owed to others.
- Is the price fair?n/a
- No P/E: the exchange publishes none when the last four quarters show a loss.
Size and price
As of Oct 20, 2026.
market cap · NT$12.0B
P/E · market median 19.9
dividend yield
The price chart appears once Ryufin has collected a month of closes (collecting since Oct 20, 2026).
The latest report
H1 2026, year to date, consolidated.
- Revenue
- NT$1M
- Operating income-7252% of revenue
- −NT$98M
- Net income
- −NT$96M
- Earnings per share
- −NT$1.83
- Total assets
- NT$364M
- Equity
- NT$345M
- Book value per share
- NT$6.58
Also in biotech and medical
The largest listed peers in Taiwan, by market cap.
- 6446.TW PharmaEssentia
- $15.2B
- 6919.TW Caliway
- $3.6B
- 7799.TW HNMC
- $2.2B
- 6472.TW Bora
- $1.6B
- 6949.TW Pell BMT
- $1.5B
- 1795.TW Lotus Pharm
- $1.5B
Source: Taiwan Stock Exchange and Taipei Exchange OpenAPI, published on data.gov.tw under the Open Government Data License, version 1.0. Ryufin computed the answers, market cap and growth rates from that data. US dollar figures use the BIS TWD/USD rate. Prices are end of day. Price history on Ryufin starts on Oct 20, 2026 and grows by one close each trading day.